CA3226869A1 - Substituted pyridine derivatives as sarm1 inhibitors - Google Patents
Substituted pyridine derivatives as sarm1 inhibitors Download PDFInfo
- Publication number
- CA3226869A1 CA3226869A1 CA3226869A CA3226869A CA3226869A1 CA 3226869 A1 CA3226869 A1 CA 3226869A1 CA 3226869 A CA3226869 A CA 3226869A CA 3226869 A CA3226869 A CA 3226869A CA 3226869 A1 CA3226869 A1 CA 3226869A1
- Authority
- CA
- Canada
- Prior art keywords
- imidazol
- compound
- pyridin
- alkyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163226557P | 2021-07-28 | 2021-07-28 | |
| US63/226,557 | 2021-07-28 | ||
| US202263305103P | 2022-01-31 | 2022-01-31 | |
| US63/305,103 | 2022-01-31 | ||
| US202263368034P | 2022-07-08 | 2022-07-08 | |
| US63/368,034 | 2022-07-08 | ||
| PCT/US2022/038577 WO2023009663A1 (en) | 2021-07-28 | 2022-07-27 | Substituted pyridine derivatives as sarm1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3226869A1 true CA3226869A1 (en) | 2023-02-02 |
Family
ID=85087993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3226869A Pending CA3226869A1 (en) | 2021-07-28 | 2022-07-27 | Substituted pyridine derivatives as sarm1 inhibitors |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11629136B1 (enExample) |
| EP (1) | EP4376840A4 (enExample) |
| JP (1) | JP2024528036A (enExample) |
| KR (1) | KR20240041987A (enExample) |
| AU (1) | AU2022320699A1 (enExample) |
| CA (1) | CA3226869A1 (enExample) |
| CL (1) | CL2024000239A1 (enExample) |
| CO (1) | CO2024001716A2 (enExample) |
| IL (1) | IL310403A (enExample) |
| MX (1) | MX2024001322A (enExample) |
| TW (1) | TW202313009A (enExample) |
| WO (1) | WO2023009663A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4192828A1 (en) | 2020-08-04 | 2023-06-14 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
| US11945796B2 (en) | 2020-09-16 | 2024-04-02 | Nura Bio, Inc. | Substituted pyridine derivatives as SARM1 inhibitors |
| US20240208923A1 (en) | 2021-03-10 | 2024-06-27 | Jnana Therapeutics Inc. | Small molecule inhibitors of mammalian slc6a19 function |
| CN113655155A (zh) * | 2021-07-28 | 2021-11-16 | 任贤金 | 一种测定sph3127有关物质的方法 |
| TW202313009A (zh) | 2021-07-28 | 2023-04-01 | 美商努拉生物科技公司 | 作為sarm1抑制劑之經取代的吡啶衍生物 |
| EP4562001A1 (en) * | 2022-07-27 | 2025-06-04 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
| CN120424050A (zh) * | 2024-02-05 | 2025-08-05 | 科辉智药(深圳)新药研究中心有限公司 | 作为sarm1酶活性抑制剂的吡啶类化合物及其应用 |
| WO2025179205A1 (en) * | 2024-02-23 | 2025-08-28 | Nura Bio, Inc. | Methods for the treatment of neurological disorders |
| WO2026080488A1 (en) | 2024-10-09 | 2026-04-16 | Genentech, Inc. | Heterocyclic compounds for the treatment of neurodegenerative diseases |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999018096A1 (en) | 1997-10-02 | 1999-04-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| EP1427413A2 (en) | 2001-09-13 | 2004-06-16 | Synta Pharmaceuticals Corporation | 2-aroylimidazole compounds for treating cancer |
| DE102004009933A1 (de) | 2004-02-26 | 2005-09-15 | Merck Patent Gmbh | Verwendung von Thiadiazolharnstoffderivaten |
| JP2007535551A (ja) | 2004-04-28 | 2007-12-06 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｒｏｃｋおよび他のプロテインキナーゼの阻害剤として有用な組成物 |
| PE20060426A1 (es) * | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
| AU2008310115B2 (en) | 2007-10-09 | 2013-06-27 | Merck Patent Gmbh | N- ( pyrazole- 3 -yl) -benzamide derivatives as glucokinase activators |
| WO2009114552A1 (en) * | 2008-03-10 | 2009-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Heteroaryl compounds, compositions, and methods of use in cancer treatment |
| US8785468B2 (en) | 2009-02-13 | 2014-07-22 | Amgen Inc. | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions |
| WO2012049161A1 (en) | 2010-10-13 | 2012-04-19 | Glaxo Group Limited | 3 -amino- pyrazole derivatives useful against tuberculosis |
| WO2012050141A1 (ja) | 2010-10-14 | 2012-04-19 | 住友化学株式会社 | ヘテロ芳香環化合物およびその有害生物防除用途 |
| CN108299400B (zh) | 2013-03-14 | 2021-02-19 | 达特神经科学(开曼)有限公司 | 作为pde4抑制剂的取代的吡啶和取代的吡嗪化合物 |
| AR096393A1 (es) | 2013-05-23 | 2015-12-30 | Bayer Cropscience Ag | Compuestos heterocíclicos pesticidas |
| EP3119774A1 (en) | 2014-03-17 | 2017-01-25 | reMynd NV | Oxadiazole compounds |
| WO2015175704A1 (en) | 2014-05-14 | 2015-11-19 | The Regents Of The University Of California | Inhibitors of bacterial dna gyrase with efficacy against gram-negative bacteria |
| JP2017521464A (ja) | 2014-07-24 | 2017-08-03 | バイエル・ファルマ・アクティエンゲゼルシャフト | グルコース輸送阻害剤 |
| HK1248070A1 (zh) | 2015-05-18 | 2018-10-12 | 转化药物开发有限责任公司 | 作为激酶抑制剂的杂环化合物 |
| US20170355708A1 (en) | 2016-06-09 | 2017-12-14 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| AU2017362571A1 (en) | 2016-11-21 | 2019-07-11 | Translational Drug Development, Llc | Heterocyclic compounds as kinase inhibitors |
| EP3801503A4 (en) | 2018-06-07 | 2021-12-08 | Disarm Therapeutics, Inc. | INHIBITORS OF SARM1 |
| EP3930849B1 (en) | 2019-02-28 | 2025-02-19 | Kezar Life Sciences | Thiazole derivatives as protein secretion inhibitors |
| US12624025B2 (en) * | 2019-06-06 | 2026-05-12 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| WO2020252229A2 (en) * | 2019-06-14 | 2020-12-17 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| US12441719B2 (en) * | 2019-09-12 | 2025-10-14 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| MX2022008395A (es) * | 2020-01-07 | 2022-09-26 | Disarm Therapeutics Inc | Inhibidores de sarm1. |
| WO2021207302A1 (en) | 2020-04-09 | 2021-10-14 | Disarm Therapeutics, Inc. | Indazole derivatives as inhibitors of sarm1 |
| EP4192828A1 (en) | 2020-08-04 | 2023-06-14 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
| TWI904906B (zh) | 2020-08-24 | 2025-11-11 | 美商達薩瑪治療公司 | Sarm1之抑制劑 |
| US11945796B2 (en) | 2020-09-16 | 2024-04-02 | Nura Bio, Inc. | Substituted pyridine derivatives as SARM1 inhibitors |
| TW202313009A (zh) | 2021-07-28 | 2023-04-01 | 美商努拉生物科技公司 | 作為sarm1抑制劑之經取代的吡啶衍生物 |
| EP4562001A1 (en) | 2022-07-27 | 2025-06-04 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
-
2022
- 2022-07-27 TW TW111128145A patent/TW202313009A/zh unknown
- 2022-07-27 WO PCT/US2022/038577 patent/WO2023009663A1/en not_active Ceased
- 2022-07-27 US US17/875,301 patent/US11629136B1/en active Active
- 2022-07-27 KR KR1020247006685A patent/KR20240041987A/ko active Pending
- 2022-07-27 JP JP2024505223A patent/JP2024528036A/ja active Pending
- 2022-07-27 IL IL310403A patent/IL310403A/en unknown
- 2022-07-27 AU AU2022320699A patent/AU2022320699A1/en active Pending
- 2022-07-27 EP EP22850281.1A patent/EP4376840A4/en active Pending
- 2022-07-27 CA CA3226869A patent/CA3226869A1/en active Pending
- 2022-07-27 MX MX2024001322A patent/MX2024001322A/es unknown
-
2023
- 2023-03-03 US US18/178,325 patent/US12110285B2/en active Active
-
2024
- 2024-01-26 CL CL2024000239A patent/CL2024000239A1/es unknown
- 2024-02-19 CO CONC2024/0001716A patent/CO2024001716A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11629136B1 (en) | 2023-04-18 |
| IL310403A (en) | 2024-03-01 |
| EP4376840A4 (en) | 2025-05-21 |
| US20230286941A1 (en) | 2023-09-14 |
| US20230105696A1 (en) | 2023-04-06 |
| MX2024001322A (es) | 2024-04-30 |
| TW202313009A (zh) | 2023-04-01 |
| CL2024000239A1 (es) | 2024-06-07 |
| AU2022320699A1 (en) | 2024-02-29 |
| CO2024001716A2 (es) | 2024-03-07 |
| US12110285B2 (en) | 2024-10-08 |
| EP4376840A1 (en) | 2024-06-05 |
| KR20240041987A (ko) | 2024-04-01 |
| JP2024528036A (ja) | 2024-07-26 |
| WO2023009663A1 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12110285B2 (en) | Substituted pyridine derivatives as SARM1 inhibitors | |
| CA3124898C (en) | Heterocyclic compound, intermediate, preparation method therefor and application thereof | |
| US11970481B1 (en) | Substituted pyridine derivatives as SARM1 inhibitors | |
| EP3157917B1 (en) | Compounds, compositions and methods of increasing cftr activity | |
| US11945796B2 (en) | Substituted pyridine derivatives as SARM1 inhibitors | |
| CN113072542B (zh) | RORγt抑制剂及其制备方法和用途 | |
| US12030869B2 (en) | 5-membered heteroaryl carboxamide compounds for treatment of HBV | |
| US10669279B2 (en) | Imidazopyridazine compounds | |
| CA3180819A1 (en) | Substituted aminothiazoles as dgkzeta inhibitors for immune activation | |
| AU2015229188A1 (en) | Compounds, compositions, and methods for increasing CFTR activity | |
| JP2018500343A (ja) | Ｃｆｔｒ活性を増加するための化合物、組成物及び方法 | |
| CN121248511A (zh) | 用于治疗hbv的5元杂芳基甲酰胺化合物 | |
| KR20240024948A (ko) | 질환의 치료를 위한 베타-락탐 유도체 | |
| JP2011516485A (ja) | Ｉｔｐｋｂ阻害剤としての化合物および組成物 | |
| JP2024529508A (ja) | ピロロ［２，３－ｂ］ピリジンＰＧＤＨ阻害剤、および製造方法ならびに使用方法 | |
| US20120122843A1 (en) | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | |
| CA3015166C (en) | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | |
| CN102574841A (zh) | 调节硬脂酰-coa去饱和酶的吡唑衍生物 | |
| EP4562001A1 (en) | Substituted pyridine derivatives as sarm1 inhibitors | |
| US20260008760A1 (en) | Dipeptidyl peptidase 1 inhibitors and uses thereof | |
| WO2025207539A1 (en) | Sarm1 inhibitors | |
| CA2885167A1 (en) | Inhibitors of viral replication, their process of preparation and their therapeutical uses | |
| JP4903355B2 (ja) | フタラジノン誘導体 | |
| CN114671878B (zh) | 取代的含氮双环化合物及其用途 | |
| EA051437B1 (ru) | Замещенные производные пиридина в качестве ингибиторов sarm1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240724 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240724 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250718 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250718 |